We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

InSights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Global Review Finds Gaps in Pneumococcal Vaccine Policies for High-Risk Children

Source: Pharmacy Times articles The study found that only 38% of nations have risk-based pneumococcal vaccine policies. Read More

Tyk2 Inhibition Prevents Islet Inflammation and Delays Type 1 Diabetes Development in Mice

Source: Pharmacy Times articles New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug. Read More

Specialty Pharmacy at a Crossroads, Say Attendees at Asembia’s AXS25 Summit

Source: Pharmacy Times articles Specialty pharmacy experts and key opinion leaders gathered at Asembia’s AXS25 Summit and discussed critical insights in interviews with Pharmacy Times®. Read More

AUC 5 vs AUC 6: MUSC Study Highlights the Tradeoffs in Neoadjuvant Breast Cancer Treatment

Source: Pharmacy Times articles Lacy La Fever, PharmD, MS, discussed outcomes associated with different carboplatin AUC dosing strategies. Read More

Study Finds Endometriosis May Be Linked to Traumatic Experiences

Source: Pharmacy Times articles These findings demonstrate an association that is independent of the disease’s genetic predisposition. Read More
Latest Data

Latest Publications

Single-Nucleotide Polymorphisms Related to Multiple Myeloma Risk: A Systematic Review and Meta-Analysis

Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks...

Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review

Cancers (Basel). 2025 Mar 24;17(7):1081. doi: 10.3390/cancers17071081. ABSTRACT...

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Cancers (Basel). 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. ABSTRACT Background:...

Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis

Curr Probl Cancer. 2025 Apr 3;56:101202. doi: 10.1016/j.currproblcancer.2025.101202. Online ahead...

Email

info@myeloma360.com